Trilobatin-mediated MANF signaling regulates mitochondrial–endoplasmic reticulum homeostasis and ameliorates MASLD

Background and Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by inflammation, oxidative stress, and mitochondrial dysfunction driven by dysregulated hepatic lipids. As an ER-resident protein, mesencephalic astrocyte-derived neurotrophic factor (MANF) modulates inflammation, oxidative stress, and metabolic homeostasis to mediate hepatic repair. Trilobatin (TLB), a natural food additive with anti-inflammatory and antioxidant activities, remains uncharacterized for its capacity to alleviate MASLD via MANF-dependent regulation of mitochondria-endoplasmic reticulum crosstalk and lipid metabolism. This study aims to investigate the effects of TLB on MASLD and its underlying mechanisms. Experimental Approach: High-fat diet-induced MASLD mice were used to evaluate TLB effects on lipid metabolism, inflammation, oxidative status, and liver pathology. Transcriptomics and untargeted metabolomics were combined to identify core pathways, while molecular docking and molecular dynamics simulations predicted TLB-MANF binding. In palmitate/oleate-challenged lipotoxic HepG2 cells, we detected MANF signaling and MAMs-related IP3R/GRP75/VDAC1, and MANF knockdown validated the mechanism whereby TLB rescues metabolic disturbance and MAMs function. Key Results: TLB attenuates hepatic injury and steatosis in MASLD mice in a dose-dependent manner. Mechanistically, TLB competitively binds to and upregulates MANF, restores MAMs protein expression, suppresses inflammation and oxidative stress, and maintains intracellular calcium homeostasis. It also ameliorates lipid dysregulation, remodels lipid profiles, and improves β-oxidation and mitochondrial function. MANF knockdown abolishes TLB’s protective effects in lipotoxic HepG2 cells. Conclusions and Implications: This study expands the pharmacological profile of TLB and shows that TLB prevents MASLD by regulating MANF signaling and MAMs function to reverse lipid dysregulation, identifying the MANF–MAMs axis as a promising target for MASLD intervention.

Authors

Institutions

Publication Details

Published
2026-11-12
DOI
https://doi.org/10.22541/authorea.15012118/v1
Primary Topic
Liver Disease Diagnosis and Treatment
Type
preprint
Controls
|||
ALL TIME
JAN
FEB
MAR
APR
MAY
JUN
JUL
AUG
SEP
OCT
NOV
preprint

Trilobatin-mediated MANF signaling regulates mitochondrial–endoplasmic reticulum homeostasis and ameliorates MASLD

Jing An, Shangheng Fan, Renxue Xie, Qi Wang et al.
Liver Disease Diagnosis and Treatment
preprint

Trilobatin-mediated MANF signaling regulates mitochondrial–endoplasmic reticulum homeostasis and ameliorates MASLD

Jing An, Shangheng Fan, Renxue Xie, Qi Wang, Youbo Yu, Yan Yang
preprint en

Abstract

Background and Purpose: Metabolic dysfunction-associated steatotic liver disease (MASLD) is characterized by inflammation, oxidative stress, and mitochondrial dysfunction driven by dysregulated hepatic lipids. As an ER-resident protein, mesencephalic astrocyte-derived neurotrophic factor (MANF) modulates inflammation, oxidative stress, and metabolic homeostasis to mediate hepatic repair. Trilobatin (TLB), a natural food additive with anti-inflammatory and antioxidant activities, remains uncharacterized for its capacity to alleviate MASLD via MANF-dependent regulation of mitochondria-endoplasmic reticulum crosstalk and lipid metabolism. This study aims to investigate the effects of TLB on MASLD and its underlying mechanisms. Experimental Approach: High-fat diet-induced MASLD mice were used to evaluate TLB effects on lipid metabolism, inflammation, oxidative status, and liver pathology. Transcriptomics and untargeted metabolomics were combined to identify core pathways, while molecular docking and molecular dynamics simulations predicted TLB-MANF binding. In palmitate/oleate-challenged lipotoxic HepG2 cells, we detected MANF signaling and MAMs-related IP3R/GRP75/VDAC1, and MANF knockdown validated the mechanism whereby TLB rescues metabolic disturbance and MAMs function. Key Results: TLB attenuates hepatic injury and steatosis in MASLD mice in a dose-dependent manner. Mechanistically, TLB competitively binds to and upregulates MANF, restores MAMs protein expression, suppresses inflammation and oxidative stress, and maintains intracellular calcium homeostasis. It also ameliorates lipid dysregulation, remodels lipid profiles, and improves β-oxidation and mitochondrial function. MANF knockdown abolishes TLB’s protective effects in lipotoxic HepG2 cells. Conclusions and Implications: This study expands the pharmacological profile of TLB and shows that TLB prevents MASLD by regulating MANF signaling and MAMs function to reverse lipid dysregulation, identifying the MANF–MAMs axis as a promising target for MASLD intervention.

Zunyi Medical University (CN), First People’s Hospital of Zunyi (CN)
Liver Disease Diagnosis and Treatment
AI Navigator

Ask Laika to Summarize, Analyze, and Connect papers live on the map.

Summarize Papers & Methodologies

Extract key findings, datasets, and comparative methods across publications.

Benchmark Rankings & Visual Analytics

Rank top research institutions, authors, funders, topics, and journals by Field-Weighted Citation Impact (FWCI) and paper volume with instant charts.

Connect Distant Disciplines

Bridge topological clusters on the map to find hidden collaborative intersections.

Laika access coming soon